title: [Erythrocyte aggregation and retinal vein occlusion. Preliminary data for a randomized study on the efficacy of anti-erythrocyte aggregation (troxerutin) in retinal vein occlusion].
abstract: Erythrocyte aggregation (EAg) is one of the principal determinants of blood viscosity at low shearing rates (slow flow). The retinal venous circulation, characterised by a slow circulatory rate and a high resistance to flow, creates a favourable environment for the formation of erythrocyte aggregates. EAg and other laboratory parameters (haematocrit, fibrinogen, plasma proteins, clotting) were measured in 64 patients presenting with retinal vein occlusion (RVO) and 64 controls matched for age, sex, risk factors (HT, diabetes, smoking) and concomitant vascular disease. Statistical analysis of the results demonstrated a significant difference between the RVO group and the control group for fibrinogen (p = 0.03) and erythrocyte aggregation (p = 0.00003 for the aggregation index at 10 sec and p = 0.0002 for the threshold of partial dissociation). The rise in the fibrinogen level alone cannot explain the increased erythrocyte aggregation. These results demonstrate that the increased EAg largely explains the hyperviscosity reported by other authors and suggest that it plays an important role in the pathogenesis of RVO.
authors.forename: A
authors.initials: A
authors.lastname: Glacet-Bernard
authors.forename: G
authors.initials: G
authors.lastname: Coscas
authors.forename: F
authors.initials: F
authors.lastname: Lelong
authors.forename: A
authors.initials: A
authors.lastname: Chabanel
authors.forename: M
authors.initials: M
authors.lastname: Samama
authors.forename: A
authors.initials: A
authors.lastname: Taccoen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004903:Erythrocyte Aggregation; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000097:blood*
chemical_list: D005340:Fibrinogen
vernacular_title: Agrégation érythrocytaire et occlusions veineuses rétiniennes. Données préliminaires à une étude randomisée sur l'efficacité d'un anti-agrégant érythrocytaire (troxérutine) au cours des occlusions veineuses rétiniennes.